Lawyers USA Your Business Partner

Pfizer to pay $142.1 million over marketing of epilepsy drug 

By: Tony Ogden
Published: January 31, 2011

Tags: marketing, Neurontin, Pfizer, racketeering

Pfizer, the drug maker, has been ordered to pay a total of $142.1 million in damages for violating federal racketeering laws in the marketing of its epilepsy drug Neurontin.

Drug litigation in review 2010 

By: Tony Ogden
Published: January 4, 2011

Tags: Accutane, Allergan, antidepressant, Avandia, AztraZeneca, Botox, Botox litigation, Department of Justice, DOJ, epilepsy, failure to warn, GlaxoSmithKline, heart attack, hormone replacement therapy, hormone replacement therapy litigation, Johnson & Johnson, Levaquin, Neurontin, Paxil, Pfizer, Premarin, Prempro, Provera, Roche, Seroquel, Wyeth

Much like 2009, 2010 was a busy year for prescription drug suits.

Pfizer settles Neurontin wrongful death suit 

By: Nora Tooher
Published: May 18, 2010

Tags: Neurontin, off-label uses, Pfizer, wrongful death

A settlement has been reached in the third Neurontin wrongful death case, which was scheduled to begin trial Tuesday in U.S. District Court in Nashville, Tenn.

Pfizer said to settle Neurontin suicide suit for $400K 

By: Pat Murphy
Published: April 2, 2010

Tags: Neurontin, product liability, wrongful death

Pfizer, Inc., agreed to pay about $400,000 to settle a lawsuit mid-trial that blamed its Neurontin epilepsy medicine for helping cause a Massachusetts man’s suicide, two people familiar with the accord said.

Jurors in Neurontin trial hear opening arguments 

By: Nora Tooher
Published: March 31, 2010

Tags: Neurontin, off-label uses, Pfizer

BOSTON – Plaintiffs’ lawyer Ronald Rosenkranz urged jurors Wednesday to hold Pfizer Inc. liable for the death of Hartley Shearer, who committed suicide in 2002 after taking Neurontin for 16 months.

Jury selection begins in Neurontin suicide trial 

By: Nora Tooher
Published: March 29, 2010

Tags: Neurontin, off-label uses, Pfizer

BOSTON – Jury selection began Monday in the second wrongful death trial alleging Pfizer’s off-label promotion of its anti-epilepsy drug Neurontin caused a patient to commit suicide.

Pfizer ordered to pay $142M for Neurontin marketing fraud 

By: Nora Tooher
Published: March 26, 2010

Tags: Kaiser, Neurontin, off-label uses, Pfizer

BOSTON – A federal jury Thursday found that Pfizer violated anti-racketeering laws in promoting its epilepsy drug Neurontin for unapproved uses and must pay at least $142 million in damages.

Neurontin class decertification upheld 

By: Nora Tooher
Published: January 28, 2010

Tags: class action, Food and Drug Administration, Neurontin

A Pennsylvania appellate court has affirmed the 2009 decertification of a Neurontin class action.

The second trial in the Neurontin multi-district litigation based in Boston is scheduled to begin March 29.

Drug litigation preview 

By: Nora Tooher
Published: January 14, 2010

Tags: Avandia, Botox, Digitek, drug litigation, FDA, Food and Drug Administration, hormone replacement therapy, Neurontin, off-label uses, preemption, Prempro, Vioxx, whistleblower, Wyeth v. Levine

Plaintiffs’ lawyers are gearing up for a slew of pharmaceutical product liability trials in 2010.

While no case has the magnitude of the massive $4.85 billion Vioxx settlement in 2007, the trials represent a welcome return to courtroom action on the pharmaceutical front for plaintiffs’ lawyers.

Neurontin trial dismissed 

By: Nora Tooher
Published: July 30, 2009

Tags: Neurontin

BOSTON – In a surprise move, the first Neurontin trial has ended with a dismissal, after an anonymous donor offered to put money in a trust fund for the 10-year-old daughter of a Massachusetts woman who committed suicide two years after taking the anti-seizure drug.